Significance of palpable tendon friction rubs in early diffuse cutaneous systemic sclerosis

Arthritis Care and Research

Volumn 65, Issue 8, 2013, Pages 1385-1389

  Doré, Adam ^a,b   Lucas, Mary ^c   Ivanco, Dana ^c   Medsger, Thomas A ^c   Domsic, Robyn T ^c  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CYCLOPHOSPHAMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENICILLAMINE; PREDNISONE; RIBONUCLEOPROTEIN ANTIBODY;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS; FEMALE; FINGER ULCER; FOLLOW UP; FRICTION; GASTROINTESTINAL DISEASE; HEART DISEASE; HUMAN; JOINT CONTRACTURE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PHYSICAL EXAMINATION; PROGNOSIS; PULMONARY HYPERTENSION; RISK FACTOR; SKINFOLD; SKINFOLD THICKNESS; SURVIVAL RATE; SYSTEMIC SCLEROSIS; TENDON DISEASE; TENDON FRICTION RUB;

EID: 84881324575     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.21964     Document Type: Article

References (13)

1. Black CA, Denton CP,. Management of systemic sclerosis. Br J Rheumatol 1995; 34: 3-7.
2. Silman AJ,. Scleroderma and survival. Ann Rheum Dis 1991; 50: 267-9.
3. Hesselstrand R, Scheja A, Akesson A,. Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis 1998; 57: 682-6.
4. Scussel-Lonzetti L, Joyal F, Raynauld JP, Roussin A, Rich E, Goulet JR, et al. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore) 2002; 81: 154-67.
5. Westphal C,. Zwei falle von schlerodermie. Charite Annalen (Berlin) 1876; 3: 341-60.
6. Shulman LE, Kurban AK, Harvey AM,. Tendon friction rubs in progressive systemic sclerosis (scleroderma). Trans Assoc Am Physicians 1961; 74: 378-88.
7. Rodnan GP, Medsger TA,. The rheumatic manifestations of progressive systemic sclerosis (scleroderma). Clin Orthop Relat Res 1968; 57: 81-92.
8. Steen VD, Medsger TA Jr,. The palpable tendon friction rub: an important physical examination finding in patients with systemic sclerosis. Arthritis Rheum 1997; 40: 1146-51.
9. Steen VD, Powell DL, Medsger TA Jr,. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988; 31: 196-203.
10. Khanna PP, Furst DE, Clements PJ, Maranian P, Indulkar L, Khanna D,. Tendon friction rubs in early diffuse systemic sclerosis: prevalence, characteristics and longitudinal changes in a randomized controlled trial. Rheumatology (Oxford) 2010; 49: 955-9.
11. Domsic RT, Rodriguez-Reyna T, Lucas M, Fertig N, Medsger TA Jr,. Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma. Ann Rheum Dis 2011; 70: 104-9.
12. Kao AH, Lacomis D, Lucas M, Fertig N, Oddis CV,. Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum 2004; 50: 209-15.
13. Penn H, Howie AJ, Kingdon EJ, Bunn CC, Stratton RJ, Black CM, et al. Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM 2007; 100: 485-94.